UK markets closed

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.8001+0.8201 (+20.61%)
As of 02:48PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.9800
Bid4.8200 x 3100
Ask4.8300 x 1400
Day's range4.3800 - 5.4600
52-week range3.5300 - 11.3600
Avg. volume7,645,510
Market cap570.204M
Beta (5Y monthly)1.46
PE ratio (TTM)N/A
EPS (TTM)-6.2300
Earnings date28 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.40
  • Yahoo Finance Video

    Novavax stock rises on Covid vaccine dispute settlement

    Shares of Novavax (NVAX) are rising after the company moves to settle a dispute over a canceled Covid vaccine purchase agreement. The company will pay up to $475 million over the next 5 years to global vaccine organization, Gavi, The Vaccine Alliance. Yahoo Finance Anchors Rachelle Akuffo and Akiko Fujita break down the latest development for the company and what it means moving forward. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino

  • Yahoo Finance

    Novavax resolves Gavi dispute over COVID-19 vaccines

    Novavax has resolved a potentially expensive battle with Gavi, opening up a pathway for the company to get out of the red.


    Novavax Stock Soars 25%. A Vaccine Purchase Settlement Is One Reason Why.

    Novavax was rising sharply Thursday after the vaccine maker reached a settlement with nongovernmental organization Gavi for its Covid-19 vaccine. Novavax said in a news release Thursday that it had reached a settlement related to a 2021 advance purchase agreement for its prototype Covid-19 vaccine. Gavi is an international organization that works to improve access to vaccines for children in lower-income countries.